Published in Biochem J on November 15, 1995
Immunological characterization of eristostatin and echistatin binding sites on alpha IIb beta 3 and alpha V beta 3 integrins. Biochem J (1996) 0.92
Applications of snake venom components to modulate integrin activities in cell-matrix interactions. Int J Biochem Cell Biol (2013) 0.84
Positional importance of Pro53 adjacent to the Arg49-Gly50-Asp51 sequence of rhodostomin in binding to integrin alphaIIbbeta3. Biochem J (2001) 0.83
Structural analysis of the KGD sequence loop of barbourin, an alphaIIbbeta3-specific disintegrin. J Comput Aided Mol Des (2000) 0.76
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol (1973) 47.81
A 125/115-kDa cell surface receptor specific for vitronectin interacts with the arginine-glycine-aspartic acid adhesion sequence derived from fibronectin. Proc Natl Acad Sci U S A (1985) 4.44
Platelets have more than one binding site for von Willebrand factor. J Clin Invest (1983) 2.89
Multiple adenovirus serotypes use alpha v integrins for infection. J Virol (1994) 2.86
The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci U S A (1985) 2.64
The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets. J Biol Chem (1985) 1.91
Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the gamma chain. Biochemistry (1984) 1.90
Inhibition of fibronectin binding to platelets by proteolytic fragments and synthetic peptides which support fibroblast adhesion. J Biol Chem (1985) 1.81
Role of fibrinogen alpha and gamma chain sites in platelet aggregation. Proc Natl Acad Sci U S A (1992) 1.81
Integrin-mediated cell adhesion: the extracellular face. J Biol Chem (1994) 1.66
Monoclonal antibody characterization of two distant sites required for function of the central cell-binding domain of fibronectin in cell adhesion, cell migration, and matrix assembly. J Cell Biol (1991) 1.59
Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms: evidence for a family of platelet-aggregation inhibitors. Proc Natl Acad Sci U S A (1990) 1.55
Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J Biol Chem (1993) 1.53
Solution structure of kistrin, a potent platelet aggregation inhibitor and GP IIb-IIIa antagonist. Science (1991) 1.48
Trigramin. A low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein IIb-IIIa complex. J Biol Chem (1987) 1.48
The platelet fibrinogen receptor: an immunogold-surface replica study of agonist-induced ligand binding and receptor clustering. J Cell Biol (1987) 1.47
Echistatin. A potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus. J Biol Chem (1988) 1.45
Quantitative aspects of hormone-receptor interactions of high affinity. Effect of receptor concentration and measurement of dissociation constants of labeled and unlabeled hormones. Biochim Biophys Acta (1975) 1.42
Ligand dissociation constants from competition binding assays: errors associated with ligand depletion. Mol Pharmacol (1987) 1.36
Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem (1991) 1.36
A discrete sequence in a platelet integrin is involved in ligand recognition. Nature (1991) 1.29
Conformational changes in fibrinogen elicited by its interaction with platelet membrane glycoprotein GPIIb-IIIa. J Biol Chem (1993) 1.29
Ligand and cation binding are dual functions of a discrete segment of the integrin beta 3 subunit: cation displacement is involved in ligand binding. Cell (1994) 1.26
Integrin alpha IIb beta 3 (platelet GPIIb-IIIa) recognizes multiple sites in fibronectin. J Biol Chem (1991) 1.24
Arginine-glycine-aspartic acid binding leading to molecular stabilization between integrin alpha v beta 3 and its ligand. J Biol Chem (1991) 1.24
Clues for understanding the structure and function of a prototypic human integrin: the platelet glycoprotein IIb/IIIa complex. Thromb Haemost (1994) 1.23
Two-step binding mechanism of fibrinogen to alpha IIb beta 3 integrin reconstituted into planar lipid bilayers. J Biol Chem (1993) 1.21
Animal-derived antigenic variants of foot-and-mouth disease virus type A12 have low affinity for cells in culture. J Virol (1994) 1.21
Arginyl-glycyl-aspartic acid sequences and fibrinogen binding to platelets. Blood (1987) 1.20
Localization of a site interacting with human platelet receptor on carboxy-terminal segment of human fibrinogen gamma chain. Biochem Biophys Res Commun (1982) 1.09
The nuclear magnetic resonance solution structure of flavoridin, an antagonist of the platelet GP IIb-IIIa receptor. J Mol Biol (1993) 1.06
Binding interactions of kistrin with platelet glycoprotein IIb-IIIa: analysis by site-directed mutagenesis. Proteins (1993) 1.04
The interaction of thrombospondin with platelet glycoprotein GPIIb-IIIa. J Biol Chem (1989) 1.03
Elegantin and albolabrin purified peptides from viper venoms: homologies with the RGDS domain of fibrinogen and von Willebrand factor. Biochim Biophys Acta (1990) 1.00
Mambin, a potent glycoprotein IIb-IIIa antagonist and platelet aggregation inhibitor structurally related to the short neurotoxins. Biochemistry (1992) 0.99
Dendroaspin: a potent integrin receptor inhibitor from the venoms of Dendroaspis viridis and D. jamesonii. Biochem Soc Trans (1993) 0.97
Interaction of disintegrins with the alpha IIb beta 3 receptor on resting and activated human platelets. Biochem J (1994) 0.93
Binding of the snake venom-derived proteins applaggin and echistatin to the arginine-glycine-aspartic acid recognition site(s) on platelet glycoprotein IIb.IIIa complex inhibits receptor function. J Biol Chem (1990) 0.90
Kistrin, an integrin antagonist, blocks endocytosis of fibrinogen into guinea pig megakaryocyte and platelet alpha-granules. J Clin Invest (1993) 0.89
Some properties and the complete primary structures of two reduced and S-carboxymethylated polypeptides (S5C1 and S5C10) from Dendroaspis jamesoni kaimosae (Jameson's mamba) venom. Biochim Biophys Acta (1979) 0.89
Halysin, an antiplatelet Arg-Gly-Asp-containing snake venom peptide, as fibrinogen receptor antagonist. Biochem Pharmacol (1991) 0.88
Ligand binding to GPIIb-IIIa: a status report. Semin Thromb Hemost (1992) 0.87
Three-dimensional structure of the RGD-containing neurotoxin homologue dendroaspin. Nat Struct Biol (1994) 0.86
The residues AGDV of recombinant gamma chains of human fibrinogen must be carboxy-terminal to support human platelet aggregation. Thromb Haemost (1992) 0.86
Apparent competitive inhibition of radioligand binding to receptors: experimental and theoretical considerations in the analysis of equilibrium binding data. J Recept Res (1988) 0.85
Triflavin, an antiplatelet Arg-Gly-Asp-containing peptide, is a specific antagonist of platelet membrane glycoprotein IIb-IIIa complex. J Biochem (1991) 0.84
Activation of human platelets by exposure to a monoclonal antibody, PM6/248, to glycoprotein IIb-IIIa. Br J Haematol (1991) 0.84
Synthetic RGD peptides derived from the adhesive domains of snake-venom proteins: evaluation as inhibitors of platelet aggregation. Biochem J (1993) 0.84
The solution structure of echistatin: evidence for disulphide bond rearrangement in homologous snake toxins. Protein Eng (1992) 0.84
Agkistrodon piscivorus piscivorus platelet aggregation inhibitor: a potent inhibitor of platelet activation. Proc Natl Acad Sci U S A (1989) 0.83
A peptide corresponding to GPIIb alpha 300-312, a presumptive fibrinogen gamma-chain binding site on the platelet integrin GPIIb/IIIa, inhibits the adhesion of platelets to at least four adhesive ligands. J Biol Chem (1992) 0.81
Beta 3 integrin derived peptide 217-230 inhibits fibrinogen binding and platelet aggregation: significance of RGD sequences and fibrinogen A alpha-chain. Biochem Biophys Res Commun (1993) 0.81
Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol (1999) 11.94
Protein interaction mapping in C. elegans using proteins involved in vulval development. Science (2000) 11.61
The detection of venous thrombosis of the legs using 125-I-labelled fibrinogen. Br J Surg (1968) 10.22
Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci U S A (1993) 9.47
Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ (2011) 9.44
Functional analysis of secreted and transmembrane proteins critical to mouse development. Nat Genet (2001) 5.67
Natural history of postoperative deep-vein thrombosis. Lancet (1969) 5.18
Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J Infect Dis (1999) 4.67
125-I-labelled fibrinogen test adapted for routine screening for deep-vein thrombosis. Lancet (1970) 4.48
ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell (2001) 4.38
Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med (1999) 4.33
Depletion of lymphocytes and diminished cytokine production in mice infected with a highly virulent influenza A (H5N1) virus isolated from humans. J Virol (2000) 3.88
Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci U S A (1998) 3.88
Molecular correlates of influenza A H5N1 virus pathogenesis in mice. J Virol (2000) 3.74
Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong. J Infect Dis (2000) 3.63
Parallel neural networks for learning sequential procedures. Trends Neurosci (1999) 3.35
The Caenorhabditis elegans locus lin-15, a negative regulator of a tyrosine kinase signaling pathway, encodes two different proteins. Genetics (1994) 3.09
Defining brain wiring patterns and mechanisms through gene trapping in mice. Nature (2001) 3.07
Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol (1993) 2.92
Molecular basis for interaction of the protein tyrosine kinase ZAP-70 with the T-cell receptor. Nature (1995) 2.79
Oral contraceptives, antithrombin- III activity, and postoperative deep-vein thrombosis. Lancet (1976) 2.77
Protein-tyrosine phosphatase Shp-2 regulates cell spreading, migration, and focal adhesion. J Biol Chem (1998) 2.67
Deep vein thrombosis of the leg. Is there a "high risk" group? Am J Surg (1970) 2.66
Structure of HIV-1 reverse transcriptase/DNA complex at 7 A resolution showing active site locations. Nature (1992) 2.52
Regulation of Hsp70 function by a eukaryotic DnaJ homolog. J Biol Chem (1992) 2.46
Low doses of heparin in prevention of deep-vein thrombosis. Lancet (1971) 2.38
Post-translational alterations in transmembrane topology of the hepatitis B virus large envelope protein. EMBO J (1994) 2.35
Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med (2001) 2.31
Activation of posterior gap gene expression in the Drosophila blastoderm. Nature (1995) 2.30
CUG repeat binding protein (CUGBP1) interacts with the 5' region of C/EBPbeta mRNA and regulates translation of C/EBPbeta isoforms. Nucleic Acids Res (1999) 2.27
Efficacy of low doses of heparin in prevention of deep-vein thrombosis after major surgery. A double-blind, randomised trial. Lancet (1972) 2.20
Zim1, a maternally expressed mouse Kruppel-type zinc-finger gene located in proximal chromosome 7. Hum Mol Genet (1999) 2.20
Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J (1996) 2.12
Postoperative deep-vein thrombosis. Effect of intensive prophylaxis. Lancet (1969) 2.09
A physiological study of elastic compression stockings in venous disorders of the leg. Br J Surg (1980) 2.06
Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem (1989) 2.05
The origin of deep vein thrombosis: a venographic study. Br J Radiol (1971) 1.96
ASPP: a new family of oncogenes and tumour suppressor genes. Br J Cancer (2007) 1.94
An interaction between the DNA repair factor XPA and replication protein A appears essential for nucleotide excision repair. Mol Cell Biol (1995) 1.92
RB regulates the stability and the apoptotic function of p53 via MDM2. Mol Cell (1999) 1.85
E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction. Genes Dev (1997) 1.85
AsMamDB: an alternative splice database of mammals. Nucleic Acids Res (2001) 1.85
Treatment of deep vein thrombosis. A trial of heparin, streptokinase, and arvin. Br Med J (1969) 1.82
High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci U S A (1997) 1.81
Coronavirus protein processing and RNA synthesis is inhibited by the cysteine proteinase inhibitor E64d. Virology (1995) 1.80
Late results of treatment of deep vein thrombosis. Br Med J (1969) 1.77
Identification and characterization of a serine-like proteinase of the murine coronavirus MHV-A59. J Virol (1995) 1.76
A functional protein pore with a "retro" transmembrane domain. Protein Sci (1999) 1.73
PROC c.574_576del polymorphism: a common genetic risk factor for venous thrombosis in the Chinese population. J Thromb Haemost (2012) 1.69
Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A (1994) 1.66
Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem (2001) 1.65
The origin of thrombi in the deep veins of the lower limb: a venographic study. Br J Surg (1978) 1.65
Speciation of key arsenic metabolic intermediates in human urine. Anal Chem (2000) 1.65
Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat Med (1998) 1.64
Rhesus macaques that become systemically infected with pathogenic SHIV 89.6-PD after intravenous, rectal, or vaginal inoculation and fail to make an antiviral antibody response rapidly develop AIDS. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.64
Sugar intake, serum insulin and platelet adhesiveness in men with and without peripheral vascular disease. Postgrad Med J (1969) 1.63
Cold adaptation and the seasonal distribution of acute myocardial infarction. QJM (1999) 1.62
Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood (1995) 1.59
Mutations in XPA that prevent association with ERCC1 are defective in nucleotide excision repair. Mol Cell Biol (1995) 1.59
Determination of monomethylarsonous acid, a key arsenic methylation intermediate, in human urine. Environ Health Perspect (2000) 1.58
The work by the developing primary care team in China: a survey in two cities. Fam Pract (2000) 1.54
Apoptosis in barley aleurone during germination and its inhibition by abscisic acid. Plant Mol Biol (1996) 1.54
Mapping the Zap-70 phosphorylation sites on LAT (linker for activation of T cells) required for recruitment and activation of signalling proteins in T cells. Biochem J (2001) 1.51
Epithelial cell polarity: a major gatekeeper against cancer? Cell Death Differ (2011) 1.51
Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine. J Infect Dis (1997) 1.51
G(alpha)i2-deficient mice with colitis exhibit a local increase in memory CD4+ T cells and proinflammatory Th1-type cytokines. J Immunol (1997) 1.49
Antithrombin-TRI (Ala382 to Thr) causing severe thromboembolic tendency undergoes the S-to-R transition and is associated with a plasma-inactive high-molecular-weight complex of aggregated antithrombin. Br J Haematol (1995) 1.47
Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion. Proc Natl Acad Sci U S A (1997) 1.46
Occurrence of monomethylarsonous acid in urine of humans exposed to inorganic arsenic. Chem Res Toxicol (2000) 1.45
Simultaneous stochastic sensing of divalent metal ions. Nat Biotechnol (2000) 1.44
Late-onset homozygous protein C deficiency. Lancet (1991) 1.43
Region-specific transcriptional changes following the three antidepressant treatments electro convulsive therapy, sleep deprivation and fluoxetine. Mol Psychiatry (2006) 1.42
Lipid peroxides and atherosclerosis. BMJ (1989) 1.41
Influence of whole blood on standard curve for heparin measurement--possible heparin binding by red cells. Thromb Haemost (1989) 1.39
Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet (1994) 1.39
Lung function test findings in patients with chronic fatigue syndrome (CFS) Aust N Z J Med (1996) 1.39
The effect of low molecular weight heparin on intimal hyperplasia in vein grafts. Eur J Vasc Surg (1994) 1.39
Interstrand cross-links induce DNA synthesis in damaged and undamaged plasmids in mammalian cell extracts. Mol Cell Biol (1999) 1.39
Fibrinolytic activity and postoperative deep-vein thrombosis. Lancet (1974) 1.39
An objective study of alternative methods of heparin administration. Thromb Res (1980) 1.38
Efficacy of low-dose heparin in prevention of extensive deep-vein thrombosis in patients undergoing total-hip replacement. Lancet (1976) 1.38
Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution. Structure (1995) 1.37
Review of present status of prophylaxis of venous thromboembolism. Proc R Soc Med (1974) 1.37
Leukocyte telomere length is associated with cognitive performance in healthy women. Neurobiol Aging (2008) 1.36
p21-activated kinase 1 plays a critical role in cellular activation by Nef. Mol Cell Biol (2000) 1.35
A sarco/endoplasmic reticulum Ca(2+)-ATPase 3-type Ca2+ pump is expressed in platelets, in lymphoid cells, and in mast cells. J Biol Chem (1994) 1.35
Physical and functional interactions between p53 and cell cycle co-operating transcription factors, E2F1 and DP1. EMBO J (1995) 1.34
Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene (2012) 1.33
Myocardial infarction and deep-vein thrombosis. Br Med J (1971) 1.33
Inositol 1,4,5-trisphosphate-induced release of sequestered Ca2+ from highly purified human platelet intracellular membranes. Biochem J (1985) 1.33
Visualization of protein-RNA interactions in cytoplasmic polyhedrosis virus. J Virol (1999) 1.31
Acquired dysfibrinogenaemia in acute and chronic liver disease. Br J Haematol (1977) 1.30
Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. Circulation (2001) 1.29
Degradation of p27(Kip) cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex. EMBO J (1999) 1.28
Plasma exchange and platelet function in Raynaud's phenomenon. Thromb Res (1981) 1.28
Discovery of a novel, paternally expressed ubiquitin-specific processing protease gene through comparative analysis of an imprinted region of mouse chromosome 7 and human chromosome 19q13.4. Genome Res (2000) 1.27
Endotoxaemia and renal failure in cirrhosis and obstructive jaundice. Br Med J (1976) 1.25
Some p53-binding proteins that can function as arbiters of life and death. Cell Death Differ (2006) 1.25